Biofilms & CF - The Slimy Setup
- Foundation: Defective CFTR protein → thick, dehydrated airway mucus. This static mucus layer is a perfect breeding ground for bacteria, especially Pseudomonas aeruginosa.
- Mechanism: Bacteria colonize the mucus, communicate via quorum sensing, and form a protective extracellular polysaccharide matrix (EPS).

- Consequences:
- ↑ Antibiotic resistance (physical barrier).
- Chronic, difficult-to-eradicate infections.
- Persistent inflammation & progressive lung damage.
⭐ High-Yield: The mucoid phenotype of P. aeruginosa in CF is due to alginate overproduction, a key component of the biofilm matrix that shields the bacteria from host defenses and antibiotics.
Key Pathogens - The Usual Suspects
-
Pseudomonas aeruginosa: The classic CF pathogen, notorious for forming biofilms.
- Transitions from non-mucoid to a mucoid phenotype by overproducing alginate, a key biofilm component.
- This conversion marks the shift to chronic, persistent infection.
-
Staphylococcus aureus: A common early colonizer, often preceding Pseudomonas.
- Methicillin-resistant S. aureus (MRSA) is a growing concern.
-
Burkholderia cepacia complex: Less common but associated with severe necrotizing pneumonia ("cepacia syndrome") and poor outcomes.
-
Other significant pathogens:
- Haemophilus influenzae (non-typeable)
- Aspergillus fumigatus (fungal)

⭐ The mucoid, alginate-producing phenotype of P. aeruginosa is a major virulence factor, conferring significant resistance to both antibiotics and host immune clearance.
Pathogenesis - The Vicious Cycle

- A cycle of infection, inflammation, and tissue damage perpetuates lung disease in CF.
- Initial colonization (often P. aeruginosa) → Biofilm formation → Chronic inflammation.
- Host response is dominated by a massive, ineffective influx of neutrophils.
- Neutrophils undergo necrosis/NETosis, releasing DNA, proteases (elastase), and oxidants that damage airways and contribute to the biofilm matrix.
⭐ The DNA released from necrotic neutrophils is a key structural component of the biofilm matrix. Dornase alfa (DNase) therapy targets this extracellular DNA, cleaving it to reduce sputum viscosity.
Management - The Uphill Battle
- Aggressive Antibiotic Therapy:
- Primary strategy involves high-dose, prolonged, and often cyclical courses targeting P. aeruginosa.
- Inhaled antibiotics (e.g., tobramycin, aztreonam) are crucial for delivering high concentrations directly to the lung with minimal systemic toxicity.
- Combination therapy is standard during exacerbations.
- Biofilm & Mucus Disruption:
- Dornase alfa (DNase): An enzyme that cleaves extracellular DNA in the biofilm matrix, reducing sputum viscosity.
- Hypertonic saline: Improves airway surface hydration and facilitates mucociliary clearance.
⭐ Azithromycin is used chronically not for its bactericidal effect, but for its anti-inflammatory properties and its ability to inhibit bacterial quorum sensing, a key process in biofilm maintenance.
High‑Yield Points - ⚡ Biggest Takeaways
- Cystic Fibrosis (CF), from CFTR gene mutations, features thick mucus that fosters biofilm growth.
- Pseudomonas aeruginosa is the hallmark pathogen, switching to a mucoid phenotype by overproducing alginate.
- The biofilm matrix provides a shield, leading to high antibiotic resistance and immune evasion.
- Quorum sensing orchestrates gene expression, controlling virulence factors within the biofilm.
- Chronic biofilm presence drives persistent inflammation, bronchiectasis, and progressive lung function decline.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app